Recursion Pharmaceuticals

Recursion Pharmaceuticals Treasury Stock

The Treasury Stock of Recursion Pharmaceuticals (RXRX) as of Oct 29, 2026 is 3.17 B USD. In the previous year, Treasury Stock was 2.47 B USD — a change of 28.15% (higher).

Treasury Stock

3.17 BUSD

YoY

28.15%

Last updated:

Treasury Stock of Recursion Pharmaceuticals is 2025 3.17 B USD. Treasury Stock of Recursion Pharmaceuticals was 2024 2.47 B USD. It decreases by 28.15% higher compared to the previous year.

The Recursion Pharmaceuticals Treasury Stock history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Treasury Stock
Date
Treasury Stock
Jan 1, 2019
2.33 M USD
Jan 1, 2020
7.31 M USD
Jan 1, 2021
943.14 M USD
Jan 1, 2022
1.13 B USD
Jan 1, 2023
1.43 B USD
Jan 1, 2024
2.47 B USD
Jan 1, 2025
3.17 B USD
The Recursion Pharmaceuticals Treasury Stock history
YEARTreasury StockYoY
3.17 BUSD+28.15%
2.47 BUSD+72.86%
1.43 BUSD+27.16%
1.13 BUSD+19.32%
943.14 MUSD+12,798.55%
7.31 MUSD+213.82%
2.33 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Recursion Pharmaceuticals Stock analysis

What does Recursion Pharmaceuticals do? Recursion Pharmaceuticals, Inc. makes money by developing novel therapeutics through its Recursion Operating System (OS), which integrates automation, artificial intelligence, machine learning, and in vivo validation. The company focuses on discovering medicines using advanced technologies in biology, chemistry, automation, and computer science. Its clinical programs include REC-994, REC-2282, REC-4881, and REC-3964, with REC-994 being an orally bioavailable, superoxide scavenger small molecule for treating cerebral cavernous malformations. The company generates revenue from its platform and clinical development efforts, targeting biopharmaceutical partnerships and potential future drug sales. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, leveraging its Recursion Data Universe to map biological and chemical relationships. The Recursion Operating System (OS) enables the company to rapidly translate silico hypotheses into validated insights and novel chemistry through iterative loops of wet lab biology and chemistry data. The company's platform integrates physical and digital components to create virtuous cycles, driving the discovery of novel therapeutics. Revenue is derived from its technology platform and clinical programs, with potential partnerships in the biopharmaceutical sector. The company's primary products are its Recursion Operating System (OS) and clinical programs such as REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is a small molecule designed for cerebral cavernous malformations, while the other programs are part of its broader therapeutic pipeline. The company targets biopharmaceutical companies and research institutions as potential partners for its technology and drug development services. Recursion Pharmaceuticals, Inc. monetizes its platform through licensing agreements and collaborative research deals, focusing on the discovery of novel medicines using AI-driven approaches. Recursion Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Recursion Pharmaceuticals stock

Treasury Stock of Recursion Pharmaceuticals is 3.17 B USD in 2025.

Treasury Stock of Recursion Pharmaceuticals changed from 2.47 B USD to 3.17 B USD, representing a 28.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Treasury Stock Recursion Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Treasury stock represents shares that were repurchased by the company. It reduces shareholders' equity and outstanding share count.

Treasury Stock's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Treasury Stock's Recursion Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Recursion Pharmaceuticals

All Key Metrics — Recursion Pharmaceuticals